News | Hypertension | July 25, 2023

Smidt Heart Institute’s Hypertension Center Earns Accreditation

Cedars-Sinai becomes the first center in Los Angeles, and 1 of only 3 in California, to receive American Heart Association’s Comprehensive Hypertension Certification

Research shows that patients have better outcomes when they are treated at an accredited center, such as the Hypertension Center in the Smidt Heart Institute, by physicians specialized in the disease. Photo by Getty.

Research shows that patients have better outcomes when they are treated at an accredited center, such as the Hypertension Center in the Smidt Heart Institute, by physicians specialized in the disease. Photo by Getty. 


July 25, 2023 — The Hypertension Center in the Smidt Heart Institute at Cedars-Sinai has earned accreditation from the American Heart Association, signifying that it exceeds the highest standards of care for patients with high blood pressure--a condition that affects nearly half of all U.S. adults and increases risk for heart attack, stroke and kidney failure.    

With this certification, the Smidt Heart Institute becomes the association’s only Comprehensive Hypertension Center in Los Angeles and one of only three in California. 

Research shows that patients have better outcomes when they are treated at an accredited center by physicians specialized in the disease. 

"We offer a multidisciplinary and multispecialty approach for a comprehensive evaluation and optimal management of hypertension," said Florian Rader, MD, MSc, medical director of the Hypertension Center, co-director of the Clinic for Hypertrophic Cardiomyopathy and associate director of the Noninvasive Laboratory in the Smidt Heart Institute. "Our treatment protocols include recommendations for lifestyle modifications that can help lower blood pressure, a comprehensive assessment of in-office and out-of-office blood pressure, including 48-hour automated ambulatory blood pressure monitoring, and medications that are both tolerable and convenient to take." 

Hypertension Center physicians also are among the most experienced in specialized care for people with secondary hypertension caused by primary aldosteronism (a disorder of the adrenal glands), pheochromocytoma (an often-benign tumor of the adrenal gland) or renal artery stenosis (blockage of the kidney artery often caused by cholesterol plaque buildup). 

Evaluation, testing and treatments for secondary hypertension include hormone testing and analysis, imaging of the adrenal glands and renal arteries, and surgical procedures led by specialty-trained surgeons.   

In addition to providing evidence-based treatments, the center also gives patients access to clinical trials studying new pharmacologic and device-based treatment options. 

"We are continuously aiming to make further advancements in how we diagnose and treat hypertension, including the most complex cases--which was among the criteria used in evaluating our Hypertension Center’s application for accreditation," said Natalie Bello, MD, MPH, director of Hypertension Research in the Smidt Heart Institute. "We’re always eager to explore new, more effective options for our patients." 

The American Heart Association regularly updates its accreditation criteria to reflect the latest evidence and guidelines in hypertension care. The process involves thoroughly evaluating a healthcare institution's practices and protocols. A team of experts, including physicians, researchers, and other healthcare professionals, reviews patient care, staff training, clinical research, community outreach and quality improvement initiatives. 

The Smidt Heart Institute is ranked #1 in California and #3 in the nation for Cardiology and Heart Surgery by U.S. News and World Report’s "Best Hospitals 2022-23." 

For more information: https://www.cedars-sinai.org


Related Content

News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
News | Heart Failure

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

Home February 22, 2024
Home
Subscribe Now